Dublin, Jan. 23, 2024 (GLOBE NEWSWIRE) -- The "Neuroendocrine Tumor Treatment Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering.
The neuroendocrine tumor treatment sector is poised for significant growth as advancements in clinical drug development continue to emerge. With a global market size that is expected to rise substantially, industry leaders are focusing on novel therapies to manage and improve the outcomes for patients diagnosed with these rare forms of cancer.
A recently published market research report provides an in-depth analysis of both current trends and future market scenarios, offering stakeholders a comprehensive view of the neuroendocrine tumor treatment landscape. The report delves into various product types used in the treatment of neuroendocrine tumors, including somatostatin analogs, targeted therapy, and chemotherapy, each playing a pivotal role in the management of the disease across different indications, such as lung, pancreas, and gastrointestinal tumors. The end-user analysis reveals hospitals and oncology centers among the primary sectors driving demand for these treatments.
Neuroendocrine Tumor Treatment Growth Catalyzed by Rising Prevalence
The increasing incidence of neuroendocrine tumors is a primary factor propelling the neuroendocrine tumor treatment market forward. Detailed insights into this trend are explored in the report, revealing significant growth opportunities within the sector. The report underscores how evolving treatment options, aimed at alleviating symptoms, controlling tumor growth, and using innovative radiation therapy, are influencing market dynamics.
Key Market Trends and Developments
- Clinical drug development is identified as a key trend gaining traction in the market, with drugs receiving fast-track designations from regulatory bodies for expedited development and review.
- Strategic collaborations are highlighted, showcasing how industry giants are joining forces to leverage their respective expertise in diagnostic imaging and radiopharmaceutical technology.
- The report also examines the significant role of research and development, shaping the future of treatment protocols and improving the prognosis for patients with neuroendocrine tumors.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 175 |
| Forecast Period | 2023 - 2027 |
| Estimated Market Value (USD) in 2023 | $1.94 billion |
| Forecasted Market Value (USD) by 2027 | $2.88 billion |
| Compound Annual Growth Rate | 10.4% |
| Regions Covered | Global |
A selection of companies mentioned in this report includes
- Pfizer Inc.
- F Hoffmann-La Roche AG
- Abbvie Inc.
- Novartis AG
- Sanofi SA
- Bristol-Myers Squibb Company
- Thermo Fisher Scientific Inc.
- AstraZeneca
- GlaxoSmithKline PLC
- Takeda Pharmaceutical
- Eli Lilly And Company
- Amgen Inc.
- Merck & Co. Inc.
- Boehringer Ingelheim International GmbH
- Servier
- Teva Pharmaceutical Industries Ltd.
- Ipsen Pharma SAS
- Exelixis Inc.
- Advanced Accelerator Applications SA
- Hutchison Medipharma Ltd.
- Dauntless Pharmaceuticals Inc.
- Tarveda Therapeutics
- GlycoMira Therapeutics Inc
- AVEO Pharmaceuticals Inc.
- Progenics Pharmaceuticals Inc.
- Callisto Pharmaceuticals Pvt Ltd.
- Chiasma Inc.
For more information about this report visit https://www.researchandmarkets.com/r/3rzior
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
